While competitors like semaglutide target only GLP-1 receptors, and tirzepatide hits both GLP-1 and GIP pathways, Retatrutide activates all three metabolically significant receptors: GLP-1, GIP, and glucagon
Key Takeaways GLP-1 drugs mimic a hormone your body already makes to suppress appetite and regulate blood sugar
These combinations lack standardized dosing and introduce variables that complicate research outcomes
If the peptide were made in the body, Szabo and his colleagues wrote, one would expect that over the course of decades, researchers would have identified the gene that encodes it, the cells that make it, the receptors that it interacts with, and the levels at which it occurs in the body
Only Kaiser-employed or Kaiser-affiliated prescribers can initiate the prior-authorization request
Full improvements in mood for depression often take 6 to 8 weeks